Exact Sciences, colorectal cancer
Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending
The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a small study.
ESMO 2024: Exact Sciences unveils results from cancer algorithm trial
The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting algorithm.
Exact Sciences says data support its colon cancer blood test
Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.
Exact Sciences spikes ahead of data for blood-based cancer test
Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more here.
ESMO: Exact Sciences shows off early colorectal cancer blood test data
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical data showing its blood-based test can help spot growing tumors | Presented at the annual meeting of the European Society for Medical Oncology,
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.
STAT20h
Biotech feud over the multibillion-dollar cancer blood test market spills onto social media
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...
Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...
FiercePharma3d
Exact Sciences debuts first Spanish-language Cologuard ads to drive colon cancer screening in Latino community
Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign ...
Exact Sciences Unusual Options Activity For September 16
In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...
Buy Rating for Exact Sciences: Promising CRC Screening Test Outperforms with High Accuracy and Market Potential
Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...
bovnews7d
Exact Sciences Corp (EXAS) Stock Rated Overweight by Wells Fargo
Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $64.12 which represents a slight increase of $5.74 or 9.83% from the prior close of $58.38. The stock opened at $58.46 and ...
Morningstar8d
Exact Sciences Corp EXAS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Seres Therapeutics (MCRB – Research Report), BioMarin ...